What question did this study set out to answer?

March 4, 2026

Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment.

Key Points

This study aims to explore the relationship between early prostate-specific antigen response and overall survival in metastatic hormone-sensitive prostate cancer, factoring in age, body mass index, and treatment type.
Conducted a retrospective cohort study using data from 5,048 U.S. Veterans with metastatic hormone-sensitive prostate cancer
Defined early PSA response as PSA levels ≤0.2 ng/mL at 6–12 months
Analyzed overall survival and PSA response variability based on age, BMI, and treatment type including ADT alone, ADT+docetaxel, and ADT+ARPI
Utilized Kaplan–Meier and Cox proportional hazards models for overall survival evaluation
30% of patients on ADT monotherapy achieved PSA ≤0.2 ng/mL, compared to 36% on ADT+docetaxel and 53% on ADT+ARPI (p<0.001)
Higher BMI correlated with better PSA response rates: 29% for BMI<25, 42% for BMI 25–29.9, and 47% for BMI≥30 (p=0.001)
Kaplan–Meier analysis indicated improved overall survival for those achieving PSA ≤0.2 ng/mL across all age and treatment groups
Median survival for those with PSA ≤0.2 ng/mL was not reached due to over 50% survival at 60 months

Abstract

109 Background: Prostate-specific antigen (PSA) response is a strong prognostic marker for overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), as shown in prospective trials. A rapid, deep PSA drop (≤0.2 ng/mL within 6 months) is linked to improved survival, but real-world evidence remains limited. This study examines real-world patterns of early PSA response and its prognostic significance in mHSPC, considering age, body mass index (BMI), and treatment. Methods: Retrospective cohort study of 5,048 U.S. Veterans with mHSPC using Veterans Health Administration data between 2017–2024. Early PSA response was defined as PSA ≤0.2 ng/mL at 6–12 months. OS and PSA response heterogeneity were analyzed by age, BMI, and treatment type (androgen deprivation therapy (ADT) alone, ADT+docetaxel, or ADT+androgen receptor pathway inhibitor (ARPI)). Kaplan–Meier and Cox proportional hazards models evaluated OS while chi-squared tests compared clinical characteristics. Results: Of 5,048 veterans with mHSPC, 2,572 received ADT monotherapy, 511 received ADT+docetaxel, and 1,961 received ADT+ARPI. PSA ≤0.2 ng/mL at 6–12 months was achieved in 30% of patients on ADT monotherapy, 36% with docetaxel-based therapy, and 53% on ADT+ARPI (p50% survival at 60 months; for PSA 0.2–2 ng/mL (n=1,302), MS was 52 months (ADT), 45 months (ADT+docetaxel), and 44.5 months (ARPI); for PSA 2–10 ng/mL (n=808), MS was 30 months (ADT), 32 months (ADT+docetaxel), and 25 months (ARPI); and for PSA >10 ng/mL (n=952), MS was 20 months (ADT), 22 months (ADT+docetaxel), and 16 months (ARPI). Conclusions: PSA decline to ≤0.2 ng/mL at 6–12 months was a strong predictor of OS regardless of treatment. Combination therapy with ADT+ARPI led to a more robust PSA response rates and better survival. These real-world results are consistent with clinical trial evidence, further supporting the prognostic value of early PSA kinetics as a surrogate marker for survival and clinical outcomes. Hazard model. PSA Threshold Categories Median Survival (months) Adjusted HR* 95% CI P-Value ≤0.2 NR* ref -- -- -- >0.2 to 2.0 48 1.95 1.75 2.17 <0.001 2.0 to 10 29 3.24 2.89 3.63 <0.001 10+ 19 5.76 5.17 6.42 <0.001 *NR = not reached; HR = hazard ratio.

AI에게 질문

Bookmark

Cite This Study

Panchal et al. (Sun,) studied this question.

synapsesocial.com/papers/69a7ccc3d48f933b5eed8914 https://doi.org/https://doi.org/10.1200/jco.2026.44.7_suppl.109

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark